African Horse Sickness Virus Serotype Research Articles

Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation

In previous studies we showed that a recombinant Modified Vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR−/−) against challenge. We continued these studies and determined, in the IFNAR−/− mouse model, whether the antibody responses induced by MVA-VP2 vaccination play a key role in protection against AHSV. Thus, groups of mice were vaccinated with wild type MVA (MVA-wt) or MVA-VP2 and the antisera from these mice were used in a passive immunisation experiment. Donor antisera from (a) MVA-wt; (b) MVA-VP2 vaccinated; or (c) MVA-VP2 vaccinated and AHSV infected mice, were transferred to AHSV non-immune recipient mice. The recipients were challenged with virulent AHSV together with MVA-VP2 vaccinated and MVA-wt vaccinated control animals and the levels of protection against AHSV-4 were compared between all these groups. The results showed that following AHSV challenge, mice that were passively immunised with MVA-VP2 vaccinated antisera were highly protected against AHSV disease and had lower levels of viraemia than recipients of MVA-wt antisera.Our study indicates that MVA-VP2 vaccination induces a highly protective humoral immune response against AHSV.

Development of a real time polymerase chain reaction assay for equine encephalosis virus

Equine encephalosis virus (EEV) is the cause of equine encephalosis. The disease is similar to mild forms of African horse sickness (AHS) and the two diseases are easily confused. Laboratory identification and serotyping of EEV is based on viral isolation in BHK-21cells and a viral plaque inhibition neutralisation test. These procedures are time-consuming and therefore a more rapid diagnostic assay for EEV that can distinguish EEV from African horse sickness virus (AHSV) infections was developed.The S7 (VP7) gene from 38 EEV isolates representing all seven serotypes was amplified and sequenced. A conserved region at the 5′ end of the gene was identified and used to design group-specific EEV primers and a TaqMan® MGB™ hydrolysis probe.The efficiency of the EEV real-time RT-PCR assay was 81%. The assay was specific, as it did not detect any of the nine serotypes of AHSV, nor 24 serotypes of bluetongue virus (BTV) and sensitive, with a 95% limit of detection of 102.9 TCID50/ml blood (95% confidence interval: 102.7 to 103.3).The real-time format was selected because of its convenience, sensitivity and ability to produce results rapidly.

Multiple large foreign protein expression by a single recombinant baculovirus: A system for production of multivalent vaccines

Baculovirus expression system offers the advantage of expression of several large proteins simultaneously by a single recombinant virus. To date, expression of multiple large (>100kDa) proteins has been hampered by the need to generate large constructs and repeat use of homologous sequence and promoter. The development of multi-loci baculovirus expression system overcomes these issues by enabling the recombination of large foreign sequences into different regions of the genome. In this paper, we have examined the co-expression of African horse sickness virus (AHSV) VP2 proteins from multiple serotypes in a single recombinant baculovirus. To this end, recombinant baculoviruses expressing multiple AHSV VP2 proteins were generated and it was found that up to six different AHSV serotypes (serotype 1, 3, 4, 5, 7 and 8) VP2 proteins (∼120kDa) could be expressed simultaneously from different loci of baculovirus genome. The expression of VP2 of one serotype was not significantly hindered by the presence of other serotypes, although there were slight differences in expression level between different serotypes. The expression of VP2 of further serotypes from additional loci resulted in a lesser expression level of VP2 proteins. Based on these findings, three additional recombinant baculoviruses encompassing all nine AHSV serotypes were constructed (serotypes 1, 7, 8 or serotypes 2, 4, 5 or serotypes 3, 6, 9) and each of the triple recombinant viruses exhibited similar expression level of each VP2. This system allows for the expression of a number of large proteins that has the potential to be exploited for multivalent vaccines production.

Passive transfer and rate of decay of maternal antibody againstAfrican horse sickness virus inSouthAfricanThoroughbred foals

African horse sickness is an insect-transmitted, noncontagious disease of equids caused by African horse sickness virus (AHSV). Mortality can exceed 90% in fully susceptible horse populations. A live-attenuated (modified live) cell-culture-adapted (MLV) polyvalent AHSV vaccine is widely used to control African horse sickness in endemic areas in southern Africa. Field studies detailing antibody responses of vaccinated horses are lacking. To determine antibody titres to the 9 known serotypes of AHSV in a cohort of broodmares that were regularly vaccinated with the MLV AHSV vaccine and to measure the passive transfer and rate of decay of maternal antibody to the individual virus serotypes in foals. Serum was collected from 15 mares before foaling and from their foals after foaling and monthly thereafter for 6 months. Antibody titres to each of the 9 AHSV serotypes were determined by serum virus neutralisation assay. There was marked variation in the antibody response of the mares to individual AHSV serotypes even after repeated vaccination, with consistently higher titre responses to some virus serotypes. Likewise, the duration of maternally derived antibodies in foals differed among serotypes. Data from this study confirm variation of the neutralising antibody response of individual mares to repeated vaccination with polyvalent AHSV vaccine. Virus strains of individual AHSV serotypes included in the vaccine may vary in their inherent immunogenicity. Passively acquired maternal antibodies to AHSV vary markedly among foals born to vaccinated mares, with further variation in the duration of passive immunity to individual AHSV serotypes. These data are relevant to the effective utilisation of live-attenuated AHSV vaccines in endemic regions, and potentially to the use of vaccines in response to future incursions of AHSV into previously free regions. Further studies involving a larger population will be required to determine the optimal time for vaccinating foals.

Serotype- and serogroup-specific detection of African horsesickness virus using phage displayed chicken scFvs for indirect double antibody sandwich ELISAs

There is an ongoing need for standardized, easily renewable immunoreagents for detecting African horsesickness virus (AHSV). Two phage displayed single-chain variable fragment (scFv) antibodies, selected from a semi-synthetic chicken antibody library, were used to develop double antibody sandwich enzyme-linked immunosorbent assays (DAS-ELISAs) to detect AHSV. In the DAS-ELISAs, the scFv previously selected with directly immobilized AHSV-3 functioned as a serotype-specific reagent that recognized only AHSV-3. In contrast, the one selected with AHSV-8 captured by IgG against AHSV-3 recognized all nine AHSV serotypes but not the Bryanston strain of equine encephalosis virus. Serving as evidence for its serogroup-specificity. These two scFvs can help to rapidly confirm the presence of AHSV while additional serotype-specific scFvs may simplify AHSV serotyping.

Outbreaks of African horse sickness in Senegal, and methods of control of the 2007 epidemic

Since first being detected in Nigeria in January 2007, African horse sickness virus serotype 2 (AHSV-2) has spread throughout the northern hemisphere, and was first reported in Senegal. A retrospective...

African Horse Sickness Outbreaks Caused by Multiple Virus Types in Ethiopia

African horse sickness (AHS) is associated with high morbidity and mortality in equids, especially horses. A retrospective analysis was carried out concerning 737 AHS outbreaks that occurred during 2007-2010 in Ethiopia. A total of ten outbreaks were investigated in the study period. All four forms of the disease (pulmonary, cardiac, horse sickness fever and the combined form) were observed, with the cardiac form being the most prevalent. Multiple African horse sickness virus serotypes (AHSV-2, AHSV-4, AHSV-6, AHSV-8 and AHSV-9) were detected by molecular methods (type-specific real-time RT-PCR assays), and fourteen isolates were derived from blood and tissue samples collected during 2009-2010. This is the first report of AHSV-4, AHSV-6 or AHSV-8 in Ethiopia.

An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses

A recombinant canarypox virus vectored vaccine co-expressing synthetic genes encoding outer capsid proteins, VP2 and VP5, of African horse sickness virus (AHSV) serotype 4 (ALVAC®–AHSV4) has been demonstrated to fully protect horses against homologous challenge with virulent field virus. Guthrie et al. (2009) detected weak and variable titres of neutralizing antibody (ranging from <10 to 40) 8 weeks after vaccination leading us to hypothesize that there could be a participation of cell mediated immunity (CMI) in protection against AHSV4. The present study aimed at characterizing the CMI induced by the experimental ALVAC®–AHSV4 vaccine. Six horses received two vaccinations twenty-eight days apart and three horses remained unvaccinated. The detection of VP2/VP5 specific IFN-γ responses was assessed by enzyme linked immune spot (ELISpot) assay and clearly demonstrated that all ALVAC®–AHSV4 vaccinated horses developed significant IFN-γ production compared to unvaccinated horses. More detailed immune responses obtained by flow cytometry demonstrated that ALVAC®–AHSV4 vaccinations induced immune cells, mainly CD8+ T cells, able to recognize multiple T-epitopes through all VP2 and only the N-terminus sequence of VP5. Neither VP2 nor VP5 specific IFN-γ responses were detected in unvaccinated horses. Overall, our data demonstrated that an experimental recombinant canarypox based vaccine induced significant CMI specific for both VP2 and VP5 proteins of AHSV4.

Structural Insight into African Horsesickness Virus Infection

African horsesickness (AHS) is a devastating disease of horses. The disease is caused by the double-stranded RNA-containing African horsesickness virus (AHSV). Using electron cryomicroscopy and three-dimensional image reconstruction, we determined the architecture of an AHSV serotype 4 (AHSV-4) reference strain. The structure revealed triple-layered AHS virions enclosing the segmented genome and transcriptase complex. The innermost protein layer contains 120 copies of VP3, with the viral polymerase, capping enzyme, and helicase attached to the inner surface of the VP3 layer on the 5-fold axis, surrounded by double-stranded RNA. VP7 trimers form a second, T=13 layer on top of VP3. Comparative analyses of the structures of bluetongue virus and AHSV-4 confirmed that VP5 trimers form globular domains and VP2 trimers form triskelions, on the virion surface. We also identified an AHSV-7 strain with a truncated VP2 protein (AHSV-7 tVP2) which outgrows AHSV-4 in culture. Comparison of AHSV-7 tVP2 to bluetongue virus and AHSV-4 allowed mapping of two domains in AHSV-4 VP2, and one in bluetongue virus VP2, that are important in infection. We also revealed a protein plugging the 5-fold vertices in AHSV-4. These results shed light on virus-host interactions in an economically important orbivirus to help the informed design of new vaccines.

A Comparison of Different PCR-Based Methods for the Detection of African Horsesickness Virus

Detection of African horsesickness virus (AHSV) by three different reverse transcription polymerase chain reaction (RT-PCR) based methods were compared. Primers were complementary to sequences contained in the gene encoding non-structural protein 2 of AHSV serotype 3. All three assays were group-specific for AHSV and detected all nine serotypes but not related orbiviruses. A dilution range was made of titrated chicken embryo-related cells infected with AHSV serotype 3 and, after isolating RNA from each diluted sample they were tested using the three different assays. RNA representing 0.2, 2 and 20 plaque forming units of AHSV could be detected by hemi-nested RT-PCR, PCR- enzyme-linked immunosorbent assay (PCR-ELISA) and RT-PCR respectively. In twelve samples from African horsesickness suspect field cases hemi-nested RT-PCR, intra-cerebral injection of mice and virus isolation from cell culture detected AHSV in 83%, 58% and 25% of samples respectively.

Virus-specific CD8+ T-cells detected in PBMC from horses vaccinated against African horse sickness virus

African horsesickness (AHS) is an infectious but noncontagious viral disease affecting all species of Equidae. The recall immune response of AHSV naïve horses immunised with an attenuated African horsesickness virus serotype 4 (AHSV4) was characterised using immune assays including ELISPOT, real-time PCR (qPCR) and flow cytometry. The recall immune response detected in PBMC isolated from three inoculated horses showed an upregulation of circulating B lymphocytes that correlated with elevated IL-4 mRNA expression indicative of humoral immunity, but reduced frequency of CD4+ cells. In addition to the expected antibody response, an increase in CD8+ cells was also detected. Although these CD8+ cells may be CTL, the role of these cells in immunity against AHSV still has to be determined.

Serotype Specific Primers and Gel-Based RT-PCR Assays for ‘Typing’ African Horse Sickness Virus: Identification of Strains from Africa

African horse sickness is a devastating, transboundary animal disease, that is ‘listed’ by the Office International des Epizooties (OIE). Although attenuated, inactivated and subunit vaccines have been developed for African horse sickness virus (AHSV), these are serotype-specific and their effective deployment therefore relies on rapid and reliable identification of virus type. AHSV serotype is controlled by the specificity of interactions between neutralising antibodies, and components of the outer-capsid, particularly protein VP2 (encoded by AHSV genome segment 2 (Seg-2)). We report the development and evaluation of novel gel based reverse transcription-PCR (RT–PCR) assays targeting AHSV Seg-2, which can be used to very significantly increase the speed and reliability of detection and identification (compared to virus neutralisation tests) of the nine serotypes of AHSV. Primer sets were designed targeting regions of Seg-2 that are conserved between strains within each of the AHSV serotype (types 1 to 9). These assays were evaluated using multiple AHSV strains from the orbivirus reference collection at IAH (www.reoviridae.org/dsRNA_virus_proteins/ReoID/AHSV-isolates.htm). In each case the Seg-2 primers showed a high level of specificity and failed to cross-amplify the most closely related heterologous AHSV types, or other related orbiviruses (such as bluetongue virus (BTV), or equine encephalosis virus (EEV)). The assays are rapid and sensitive, and can be used to detect and type viral RNA in blood, tissue samples, or cultivated viral suspensions within 24 h. They were used to identify AHSV strains from recent outbreaks in sub-Saharan African countries. These methods also generate cDNAs suitable for sequencing and phylogenetic analyses of Seg-2, identifying distinct virus lineages within each virus-type and helping to identify strain movements/origins. The RT-PCR methods described here provide a robust and versatile tool for rapid and specific detection and identification of AHSV serotypes 1 to 9.

Tissue Tropism of African Horsesickness Virus in the Chicken Embryo Demonstrated With the Avidin–Biotin Complex Immunoperoxidase Method

In horses, African horsesickness virus (AHSV) exhibits marked tropism for certain microvascular endothelia and components of the mononuclear phagocyte system. In this study, the tropism of a field isolate of AHSV serotype 5 was studied in 24 chicken embryos. Histopathology on embryonic tissues harvested with 12 hour intervals revealed progressive changes associated with endothelial damage. Immunolabeling demonstrated viral antigens in the microvascular endothelium of the spleen, lungs, and the mesenchymal connective tissue at the base of the neck, from 24 hours post inoculation. Subsequently, specific immunolabeling increased steadily in endothelia of these and other tissues such as skeletal and cardiac muscle, gastrointestinal smooth muscle, mesonephric glomeruli, liver, subcutis and feathers. Positive immunolabeling was also occasionally observed in circulating mononuclear cells and in Kupffer cells in the liver. It was concluded, that this isolate of AHSV displayed similar tissue tropism in the chicken embryo as in the horse.

Development and optimisation of a duplex real-time reverse transcription quantitative PCR assay targeting the VP7 and NS2 genes of African horse sickness virus

Nucleotide sequences of 52 South African isolates of African horse sickness virus (AHSV) collected during 2004–2005 and including viruses of all nine AHSV serotypes, were used to design and develop a duplex real-time reverse transcription quantitative PCR (RT-PCR) assay targeting the VP7 (S8) and NS2 (S9) genes of AHSV. The assay was optimized for detection of AHSV in fresh and frozen blood of naturally infected horses. Assay performance was enhanced using random hexamers rather than gene-specific primers for RT, and with denaturation of double-stranded RNA in the presence of random hexamers. The assay was efficient with a linear range of at least five orders of magnitude. The analytical sensitivity of the assay was 132 copies of the target genes (4125 copies per ml of blood), and the assay was at least 10-fold more sensitive than virus isolation on BHK-21 cells. The assay was also highly specific because it did not detect related orbiviruses, such as bluetongue and equine encephalosis viruses.

Standardization and Validation of an Immunoperoxidase Assay for the Detection ofAfrican Horse Sickness Virusin Formalin-Fixed, Paraffin-Embedded Tissues

An immunoperoxidase assay for the detection of African horse sickness virus (AHSV) in formalin-fixed tissues is a valuable tool in the study of the pathogenesis of the disease, as well as a useful addition to existing diagnostic tests when only preserved tissues are available. An assay that uses Hamblin antiserum in a basic avidin-biotin complex detection system was standardized and validated in accordance with the guidelines of the American Association of Veterinary Laboratory Diagnosticians Subcommittee on Standardization of Immunohistochemistry. Using 128 positive cases of African horse sickness confirmed by viral isolation and serotyping and 119 negative cases from countries where the disease has never occurred, diagnostic sensitivity and diagnostic specificity were 100% in the prime target tissues of heart and lung. There was no variation in the ability of the assay to detect all 9 serotypes of AHSV, and there was no cross-reactivity with other orbiviruses in formalin-fixed tissues. The only cross-reactivity observed was in the lungs of 2 negative cases infected with Rhodococcus equi. The assay gave good results on tissues that had been fixed in formalin for up to 365 days. Nonspecific staining was minimal provided that the standard procedures for processing and staining tissues were followed. Good immunohistochemical results were also obtained on samples fixed as long as 24 hr after death. The assay, therefore, provides a robust diagnostic tool for detection of AHSV in formalin-fixed tissues, provided the analysis is done by an experienced pathologist.

PCR detection of African horse sickness virus serogroup based on genome segment three sequence analysis

A nested reverse transcriptase (RT) polymerase chain reaction (RT-PCR), for rapid detection of African horse sickness virus (AHSV) double-stranded ribonucleic acid (dsRNA) in cell culture and tissue samples, was developed and evaluated. Using an outer pair of primers (P1 and P2), selected from genome segment three of AHSV serotype 6 (AHSV-6), the RT-PCR-based assay resulted in amplification of a 890 base pair (bp) primary PCR product. RNAs from the nine vaccine strains of AHSV, and a number of AHSV field isolates including the Central African isolates of AHSV-9 and AHSV-6, propagated in cell cultures, were detected by this assay. A second pair of nested primers (P3 and P4) was used to produce a 240-bp PCR product. The RT-PCR described below detected as little as 0.1 fg of AHSV RNA, which is equivalent to six viral particles. The nested amplification confirmed the integrity of the primary PCR product and increased the sensitivity of the PCR assay by at least 1000-fold. Application of this RT-PCR assay to clinical samples resulted in direct detection of AHSV dsRNA from blood and a variety of tissue samples collected from equines infected experimentally and naturally. The specificity studies indicated that the primary or the nested PCR products were not amplified from, closely related orbiviruses including, bluetongue virus (BTV) prototypes serotypes 1, 2, 4, 10, 16 and 17; epizootic hemorrhagic disease of deer virus (EHDV) prototypes serotypes 1 and 2; EHDV-318, Sudanese isolates of palyam serogroup of orbiviruses; total nucleic acid extracts from uninfected Vero cells; or unfractionated blood from horses and donkeys that were AHSV-seronegative and virus isolation negative. The RT-PCR provides a valuable tool for study of the epidemiology of AHSV and can be recommended for rapid diagnosis during an outbreak of the disease among susceptible equines.

Interactions vecteurs-virus : diversité des sérotypes et des souches de la peste équine africaine, et populations géographiques

The most abundant Culicoides species in an area is not inevi­tably the most competent vector species for a specific virus. Oral susceptibility, as an indicator of vector competence, is a measure of the portion of vectors taking a blood meal from an infected host that actually becomes infective. Cumulative laboratory oral susceptibility results from South Africa indicate a multivector potential for bluetongue virus (BTV) as well as for African horse sickness virus (AHSV). Considering the unique biology of potential vector competent Culicoides species one can appreciate the complex epidemiology of these diseases. The oral susceptibly of C. imicola, a proven vector of AHSV and BTV, was relatively low for most of the viral isolates and even appeared to be refractory to infection with some of the isolates used. This relatively low oral susceptibility may partly explain the low field infection prevalence of AHSV and BTV recorded in field collected midges. In South Africa, the relatively low oral susceptibility as determined for some of the isolates is easily compensated for by the high abundance of C. imicola. Differences found in the virus recovery rates of various AHSV serotypes/isolates from the various Culicoides species and even different populations of the same species emphasize the fact that, although oral susceptibility tests provide important information about a specific vector population, it provides no predictability about the behaviour of other populations with different strains of virus. Differences found in the oral susceptibility of C. imi­cola and C. bolitinos for isolates of the same serotypes of AHSV suggest coadaptation between orbiviruses and vectors present in a given locality. Real-time monitoring of vector competence might be difficult as it would require assessing local Culicoides populations using variants of orbiviruses currently in circula­tion. It needs to be emphasized that laboratory demonstration of oral susceptibility is not the only necessary step to implement a competent vector. It is, however, an indication of the ability of a vector to support virus replication and one of the critical components of vectorial capacity. Vector capacity is the relative measure of a vector population to transmit a virus to a vertebrate population. In addition to vector competence, vectorial capacity depends on the biting rate, host selection, vector survivorship, and the extrinsic incubation period of the virus.

Foyers récents de peste équine africaine en Afrique du Sud

Based on diagnostic samples received at the Agricultural Research Council – Onderstepoort Veterinary Institute (ARC-OVI), a reference centre for African horse sickness (AHS) and bluetongue (BT) for the World Organisation for Animal Health (OIE), the traditional picture on the presence and occurrence of AHS seems to have changed dramatically in South Africa. Outbreaks of AHS virus (AHSV) have increased in this country over the last three to eight years. Outbreaks tend to occur earlier in the season than normally expected. Unpredicted outbreaks of AHS during the past five years in the declared AHS-free area in the South-Western Cape has led to the temporary closure of the quarantine station in Cape Town and the ban on horse exports from South Africa with significant losses to the horse industry as a whole. In January and February 2006, outbreaks of AHSV serotype 9 have also occurred in the George/Knysna area in the Western Cape. Outbreaks in this area occurred over a relatively long period and continued into the colder months of the year. This seems to indicate that AHSV has overwintered in this frost-free area, and that it could have occurred in cycling hosts (donkeys and zebras) and/or in adult Culicoides species. Since 2001, AHS has occurred annually in the Eastern Cape, South Africa, with at least four serotypes in circulation today. In an outbreak in April 2008 in Port Elisabeth, Eastern Cape, C. bolitinos was the dominant species in the coastal areas, whereas C. imicola was the dominant one in the inland area. In the outbreak in February and March 2008 in Robertson and in Kimberley, Northern Cape, C. imicola was the dominant species. Pools of midges have been tested for virus detection during each outbreak. From the outbreak in Robertson, 13 pools were posi­tive for equine encephalosis virus (EEV) and two for BTV. From the outbreak in Kimberley, EEV was isolated from one pool of C. tuttifrutti. The role of C. tuttifrutti as a vector is still poorly understood.

Serotype-specific detection of African horsesickness virus by real-time PCR and the influence of genetic variations

Real-time PCR hybridization probe sets were tested for the specific detection of amplified genome segment 2 cDNA from all nine serotypes of African horsesickness virus (AHSV). The hybridization probes were derived from the sequences of genome segments 2 of the nine reference strains of the virus and were designed to have clearly distinguishable peak melting temperatures. Viral dsRNA from each of the serotypes was specifically detected after reverse transcription, real-time PCR and melting curve analysis. The method was used to successfully serotype a range of field isolates, although most of the these showed peak melting temperature shifts. These shifts could be related to nucleotide substitutions in the regions that are targeted by the probes. Sensitivity was demonstrated to be sufficient for use with dsRNA isolated directly from infected organ samples, making it potentially useful as a rapid diagnostic tool.

A serological survey of African horse sickness in Botswana : research communication

A retrospective serological survey of African horse sickness (AHS) in Botswana covering a 10-year period (1995-2004) is reported. The survey involved horses showing clinical symptoms of the disease; the horses had not been vaccinated against AHS. Over the period surveyed, serological evidence suggestive of infection with AHS virus (AHSV) was found in 99 clinical cases out of which 41.4% (41/99) cases were found during the 1st half (1995-1999) and 58.6 % (58/99) cases were found in the 2nd half of the survey period (2000-2004). These serological findings are discussed in relation to AHSV serotypes isolated from diseased horses in Botswana before and during the period of this serological survey.